A new article published in The Journal of Allergy and Clinical Immunology evaluated the efficacy and safety of tralokinumab in adults with moderate to severe atopic dermatitis (AD). In this randomized controlled trial, 204 adults were divided in the ratio 1:1:1:1 to receive subcutaneous tralokinumab 45 mg, 150 mg, or 300 mg or placebo, respectively, every 2 weeks for 12 weeks, with concomitant topical glucocorticoids. The results showed that after 12 weeks of therapy, tralokinumab 300 mg significantly improved the change from baseline in Eczema Area Severity Index (EASI). Greater responses were found in participants with higher concentrations of biomarkers of increased interleukin (IL)-13 activity. Furthermore, tralokinumab 300 mg-treated participants demonstrated improvements in Scoring of Atopic Dermatitis, Dermatology Life Quality Index, and pruritus numeric rating scale. Meanwhile, the most reported treatment-emergent adverse event was upper respiratory tract infection. Thus, tralokinumab treatment was associated with early and sustained improvements in AD symptoms, and an acceptable safety and tolerability profile. From the findings, it was concluded that targeting IL-13 can be an efficient intervention strategy AD treatment.